NCT06965114 2026-04-14
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
National Cancer Institute (NCI)
Phase 1/2 Recruiting
National Cancer Institute (NCI)
Nationwide Children's Hospital
University of California, San Francisco
Day One Biopharmaceuticals, Inc.
Ipsen
Dana-Farber Cancer Institute